<DOC>
	<DOCNO>NCT00002424</DOCNO>
	<brief_summary>This study see safe effective HIV drug L-756423 plus indinavir ( IDV ) compare IDV take stavudine ( d4T ) lamivudine ( 3TC ) . The study also see whether take 1 large dose L-756423/IDV day safe effective take 2 small dos twice day .</brief_summary>
	<brief_title>A Study Compare Safety Effectiveness Indinavir Combined With Stavudine Lamivudine</brief_title>
	<detailed_description>Patients randomize 1 4 treatment arm . In Group 1 , patient receive dose L-756423/IDV daily plus IDV placebo . In Group 3 , patient receive low dose L-756423/IDV twice daily ( daily dosage equal Group 1 ) plus IDV placebo . In Groups 2 4 , patient receive equal dosage IDV plus L-756423/IDV placebo . In 4 group L-756423 IDV blind investigator patient . All group receive open-label d4T 3TC . Patients routinely undergo physical exam blood urine test ensure drug ' safety tolerability , evaluate tabulation adverse event clinical assessment laboratory data . In addition , CD4+ T cell plasma viral RNA level measure quantify drug ' antiretroviral activity .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria You may eligible trial : Have HIV infection . Have level CD4 cell 100 cells/mm3 great . Have viral load 10,000 copies/ml great . Are 18 year age old . Exclusion Criteria You may eligible trial : Have ever take antiHIV drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>